Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.09 (1y: -36%)
Market Cap 45.9 M P/E(ttm)
Enterprise Value 40.34 M P/B 4.00
GENE- NAS (USA)
Genetic Technologies Limited
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.09
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 495.444
GENE's Cash to Debt is ranked lower than
917430% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.36 vs. GENE: 495.444 )
GENE' s 10-Year Cash to Debt Range
Min: 5.38   Max: No Debt
Current: 495.44
Equity to Asset 0.779
GENE's Equity to Asset is ranked lower than
1098900% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GENE: 0.779 )
GENE' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.86
Current: 0.78
0.22
0.86
Interest Coverage No Debt
GENE's Interest Coverage is ranked lower than
1388888% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10000.00 vs. GENE: No Debt )
GENE' s 10-Year Interest Coverage Range
Min: 12   Max: No Debt
Current: No Debt
F-Score: 1
Z-Score: 6.59
M-Score: -1.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -52.10
GENE's Operating margin (%) is ranked lower than
1694914% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.50 vs. GENE: -52.10 )
GENE' s 10-Year Operating margin (%) Range
Min: -202.4   Max: 5.3
Current: -52.1
-202.4
5.3
Net-margin (%) -46.7
GENE's Net-margin (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.60 vs. GENE: -46.7 )
GENE' s 10-Year Net-margin (%) Range
Min: -182.1   Max: 5
Current: -46.7
-182.1
5
ROE (%) -37.1
GENE's ROE (%) is ranked lower than
1785713% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.30 vs. GENE: -37.1 )
GENE' s 10-Year ROE (%) Range
Min: -168.8   Max: 13.8
Current: -37.1
-168.8
13.8
ROA (%) -32.2
GENE's ROA (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. GENE: -32.2 )
GENE' s 10-Year ROA (%) Range
Min: -112.9   Max: 10.2
Current: -32.2
-112.9
10.2
Revenue Growth (%) -9.6
GENE's Revenue Growth (%) is ranked lower than
2173911% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. GENE: -9.6 )
GENE' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 41.4
Current: -9.6
0
41.4
EPS Growth (%) -13.1
GENE's EPS Growth (%) is ranked lower than
5882347% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.10 vs. GENE: -13.1 )
GENE' s 10-Year EPS Growth (%) Range
Min: 0   Max: 12.7
Current: -13.1
0
12.7
ยป GENE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GENE



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 4.00
GENE's P/B is ranked lower than
1010100% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.64 vs. GENE: 4.00 )
GENE' s 10-Year P/B Range
Min: 0.58   Max: 25.5
Current: 4
0.58
25.5
P/S 4.10
GENE's P/S is ranked lower than
917430% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.43 vs. GENE: 4.10 )
GENE' s 10-Year P/S Range
Min: 0.87   Max: 64
Current: 4.1
0.87
64
PFCF 18.70
GENE's PFCF is ranked lower than
672% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.60 vs. GENE: 18.70 )
GENE' s 10-Year PFCF Range
Min: 8.3   Max: 32.5
Current: 18.7
8.3
32.5
EV-to-EBIT 3.5
GENE's EV-to-EBIT is ranked lower than
476% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. GENE: 3.5 )
GENE' s 10-Year EV-to-EBIT Range
Min: 29.5   Max: 130.9
Current: 3.5
29.5
130.9

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 7.1
GENE's Price/Net Cash is ranked lower than
2127657% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. GENE: 7.1 )
GENE' s 10-Year Price/Net Cash Range
Min: 3   Max: 49.5
Current: 7.1
3
49.5
Price/Net Current Asset Value 62.2
GENE's Price/Net Current Asset Value is ranked lower than
448% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.80 vs. GENE: 62.2 )
GENE' s 10-Year Price/Net Current Asset Value Range
Min: 0   Max: 0
Current: 62.2
Price/Tangible Book 3.8
GENE's Price/Tangible Book is ranked lower than
1136363% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. GENE: 3.8 )
GENE' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 21
Current: 3.8
1.5
21
Price/Median PS Value 0.9
GENE's Price/Median PS Value is ranked lower than
1041666% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. GENE: 0.9 )
GENE' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 7.3
Current: 0.9
0.2
7.3
Forward Rate of Return (Yacktman) -4.55
GENE's Forward Rate of Return (Yacktman) is ranked lower than
3030300% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.26 vs. GENE: -4.55 )
GENE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.9   Max: 2544
Current: -4.55
-24.9
2544

Business Description

Genetic Technologies Limited is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents globally; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.
Company Website
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:GTG.Australia, GNTLF.USA, DU8.Germany
ยป More Articles for NAS:GENE

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial